Best Stocks Under $30 Right Now → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $30.00 (30 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - HarmonicNASDAQ:HLITStock Price: $11.36 (-$0.03)P/E Ratio: 18.93Market Cap: $1.27 billionAverage Trading Volume: 2.04 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $17.20 (51.4% Upside)Harmonic Inc., together with its subsidiaries, provides broadband solutions worldwide. The company operates through Broadband and Video segments. The Broadband segment sells broadband access solutions and related services, including cOS software-based broadband access solutions to broadband operators; and cOS central cloud services, a subscription service for cOS customers. The Video segment sells video processing, production, and playout solutions and services to cable operators, and satellite and telco Pay-TV service providers, as well as to broadcast and media, including streaming media companies. Its video processing appliance solutions include network management and application software, and hardware products, such as encoders, video servers, high-density stream processing systems, and edge processors. This segment also provides VOS360 SaaS platform that provides both streaming and channel origination and distribution services; and software-as-a-service (SaaS) solutions, which enables the packaging and delivery of streaming services, including live streaming, VOD, catch-up TV, start-over TV, network-DVR and cloud-DVR services through HTTP streaming to various device along with dynamic and personal ad insertion. The company also provides technical support and professional services, such as maintenance and support, consulting, implementation, integration services, program management, technical design and planning, building and site preparation, integration and equipment installation, end-to-end system testing, and training, as well as SaaS-related support and deployment. It sells its products through its direct sales force, as well as through independent resellers and systems integrators. The company was incorporated in 1988 and is headquartered in San Jose, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - DigitalBridge GroupNYSE:DBRGStock Price: $14.64 (-$0.31)P/E Ratio: 9.45Market Cap: $2.54 billionAverage Trading Volume: 2.28 million sharesDividend Yield: 0.27%<Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $21.75 (48.6% Upside)DigitalBridge is an infrastructure investment firm specializing in digital infrastructure assets. They provide services to institutional investors. They primarily invest in data centers, cell towers, fiber networks, small cells, and edge infrastructure. DigitalBridge Group, Inc. was founded in 1991 and is headquartered in Boca Raton, Florida with additional offices in Los Angles, California, and New York New York.#3 - Clean Energy FuelsNASDAQ:CLNEStock Price: $2.48 (-$0.01)P/E Ratio: -7.09Market Cap: $553.69 millionAverage Trading Volume: 1.63 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.60 (125.8% Upside)Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.#4 - Zura BioNASDAQ:ZURAStock Price: $4.79 (+$0.11)Market Cap: $206.40 millionAverage Trading Volume: 273,913 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.83 (293.2% Upside)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.#5 - Atlas Energy SolutionsNYSE:AESIStock Price: $22.58 (-$0.14)P/E Ratio: 12.54Market Cap: $2.26 billionAverage Trading Volume: 758,376 sharesDividend Yield: 2.82%<Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.17 (11.5% Upside)Atlas Energy Solutions Inc. engages in the production, processing, and sale of mesh and sand that are used as a proppant during the well completion process in the Permian Basin of Texas and New Mexico. The company provides transportation and logistics, storage solutions, and contract labor services. It sells its products and services to oil and natural gas exploration and production companies, and oilfield services companies. Atlas Energy Solutions Inc. was founded in 2017 and is headquartered in Austin, Texas.#6 - QuanterixNASDAQ:QTRXStock Price: $16.86 (+$0.18)P/E Ratio: -17.56Market Cap: $645.23 millionAverage Trading Volume: 365,135 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $30.60 (81.5% Upside)Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here#7 - Scholar RockNASDAQ:SRRKStock Price: $13.64 (+$0.29)P/E Ratio: -6.53Market Cap: $1.09 billionAverage Trading Volume: 765,320 sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $25.17 (84.5% Upside)Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.#8 - Kimbell Royalty PartnersNYSE:KRPStock Price: $15.78 (+$0.12)P/E Ratio: 26.30Market Cap: $1.51 billionAverage Trading Volume: 351,060 sharesDividend Yield: 12.52%<Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $21.00 (33.1% Upside)Kimbell Royalty Partners, LP, together with its subsidiaries, engages in acquiring and owning mineral and royalty interests in oil and natural gas properties in the United States. It serves as the general partner of the company. The company was incorporated in 2015 and is based in Fort Worth, Texas.#9 - Dyne TherapeuticsNASDAQ:DYNStock Price: $26.62 (+$0.62)P/E Ratio: -6.71Market Cap: $2.33 billionAverage Trading Volume: 1.80 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $37.75 (41.8% Upside)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.#10 - ArdelyxNASDAQ:ARDXStock Price: $8.02 (+$0.25)P/E Ratio: -28.64Market Cap: $1.87 billionAverage Trading Volume: 6.24 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.81 (59.8% Upside)Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.#11 - Mirum PharmaceuticalsNASDAQ:MIRMStock Price: $24.78 (+$0.02)P/E Ratio: -6.68Market Cap: $1.17 billionAverage Trading Volume: 541,586 sharesConsensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $49.73 (100.7% Upside)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here#12 - BrightSpring Health ServicesNASDAQ:BTSGStock Price: $11.24Market Cap: $1.93 billionAverage Trading Volume: 2.01 million sharesConsensus Rating: Buy (11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.85 (41.0% Upside)BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.#13 - Gambling.com GroupNASDAQ:GAMBStock Price: $8.83 (-$0.29)P/E Ratio: 18.79Market Cap: $328.65 millionAverage Trading Volume: 140,442 sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $15.21 (72.3% Upside)Gambling.com Group Limited operates as a performance marketing company for the online gambling industry worldwide. It provides digital marketing services for the iGaming and social casino products. The company's focus is on online casino, online sports betting, and fantasy sports industry. It publishes various branded websites, including Gambling.com, Casinos.com, RotoWire.com, and Bookies.com. The company was incorporated in 2006 and is based in Saint Helier, Jersey.#14 - TeraWulfNASDAQ:WULFStock Price: $2.24 (+$0.01)Market Cap: $677.00 millionAverage Trading Volume: 18.68 million sharesConsensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.66 (63.3% Upside)TeraWulf Inc., together with its subsidiaries, operates as a digital asset technology company in the United States. The company develops, owns, and operates bitcoin mining facilities in New York and Pennsylvania. It is also involved in the provision of miner hosting services to third-party entities. The company was founded in 2021 and is headquartered in Easton, Maryland.#15 - Taboola.comNASDAQ:TBLAStock Price: $4.22 (-$0.18)P/E Ratio: -18.35Market Cap: $1.23 billionAverage Trading Volume: 1.35 million sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.79 (37.2% Upside)Taboola.com Ltd., together with its subsidiaries, operates an artificial intelligence-based algorithmic engine platform in Israel, the United States, the United Kingdom, Germany, and internationally. It offers Taboola, a platform that partners with websites, devices, and mobile apps to recommend editorial content and advertisements on the open web to users. The company was incorporated in 2006 and is headquartered in New York, New York.#16 - Alpine Income Property TrustNYSE:PINEStock Price: $15.67 (-$0.04)P/E Ratio: -391.75Market Cap: $213.43 millionAverage Trading Volume: 53,759 sharesDividend Yield: 7.00%<Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.35 (17.1% Upside)Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that seeks to deliver attractive risk-adjusted returns and dependable cash dividends by investing in, owning and operating a portfolio of single tenant net leased properties that are predominately leased to high-quality publicly traded and credit-rated tenants.Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here#17 - Pliant TherapeuticsNASDAQ:PLRXStock Price: $13.67 (-$0.14)Market Cap: $824.71 millionAverage Trading Volume: 384,010 sharesConsensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $45.67 (234.1% Upside)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.#18 - Vor BiopharmaNYSE:VORStock Price: $1.70 (-$0.01)P/E Ratio: -0.96Market Cap: $116.04 millionAverage Trading Volume: 288,523 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $12.50 (635.3% Upside)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.#19 - Longboard PharmaceuticalsNASDAQ:LBPHStock Price: $19.93 (-$0.19)P/E Ratio: -8.90Market Cap: $774.88 millionAverage Trading Volume: 1.14 million sharesConsensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $43.67 (119.1% Upside)Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.#20 - Cabaletta BioNASDAQ:CABAStock Price: $11.26P/E Ratio: -6.82Market Cap: $527.08 millionAverage Trading Volume: 1.06 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $34.33 (204.9% Upside)Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.#21 - Riot PlatformsNASDAQ:RIOTStock Price: $9.50 (+$0.30)P/E Ratio: 10.92Market Cap: $2.74 billionAverage Trading Volume: 26.11 million sharesConsensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $18.33 (92.9% Upside)Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through three segments: Bitcoin Mining, Data Center Hosting, and Engineering. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; and electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.#22 - SMART GlobalNASDAQ:SGHStock Price: $19.22 (+$0.26)P/E Ratio: -5.22Market Cap: $1.01 billionAverage Trading Volume: 1.07 million sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $30.70 (59.7% Upside)SMART Global Holdings, Inc., a memory-focused company, engages in the designing and development of enterprise solutions in the United States, China, Europe, and internationally. It operates through Memory Solutions, Intelligent Platform Solutions, and LED Solutions segments. The company offers dynamic random access memory modules, solid-state and flash storage, and other advanced memory solutions for networking and telecom, data analytics, artificial intelligence and machine learning applications; and supply chain services including procurement, logistics, inventory management, temporary warehousing, programming, kitting, and packaging services. It also provides Penguin Computing that focus on technical computing for core and cloud environments through HPC and AI solutions; and Penguin Edge, an edge computing solution for embedded and wireless applications including high-performance products for government, health care, industrial, and telecommunications applications. In addition, the company offers Stratus, which provides simplified, protected, and autonomous fault tolerant computing solutions in the data center and at the Edge through hardware and software services; and leading-edge solutions to education, energy, financial services, government, hyperscale, and manufacturing markets. Further, it provides LED-based products comprising blue and green LED chips based on gallium nitride, and related materials under Cree LED brand; and surface mount devices under the Cree LED XLamp and J Series brand. The company sells its products directly to original equipment manufacturers, enterprise, government and other end customers through direct sales force, e-commerce, customer service representatives, on-site field application engineers, independent sales representatives, distributors, integrators, and resellers. SMART Global Holdings, Inc. was founded in 1988 and is headquartered in Milpitas, California.#23 - Taysha Gene TherapiesNASDAQ:TSHAStock Price: $2.40 (+$0.06)P/E Ratio: -3.58Market Cap: $448.85 millionAverage Trading Volume: 2.42 million sharesConsensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.88 (186.5% Upside)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.#24 - Hamilton Insurance GroupNYSE:HGStock Price: $16.10 (+$0.07)P/E Ratio: 4.89Market Cap: $1.77 billionAverage Trading Volume: 269,716 sharesConsensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $19.80 (23.0% Upside)Hamilton Insurance Group, Ltd., through its subsidiaries, provides underwriting specialty insurance and reinsurance risks in Bermuda and internationally. The company operates Hamilton Global Specialty, Hamilton Select, and Hamilton Re underwriting platforms. The company offers casualty reinsurance products, such as commercial motor, general liability, healthcare, multiline, personal motor, professional liability, umbrella and excess casualty, and worker's compensation and employer's liability reinsurance; property reinsurance and insurance; and specialty reinsurance solutions, including accident and health, aviation and space, crisis management, mortgage, financial lines, marine and energy, and multiline specialty. In addition, it offers accident and health, cyber, energy, environmental, financial lines, fine art and specie, kidnap and ransom, mergers and acquisitions, marine and energy liability, political risk and violence, professional liability, property binders, property direct and facultative, professional lines, space, upstream energy, excess casualty, war and terrorism, allied medical, management liability, medical professionals, general liability, products liability and contractors, and small business casualty insurance plans, as well as surety and treaty reinsurance products. The company was incorporated in 2013 and is headquartered in Pembroke, Bermuda.#25 - ArterisNASDAQ:AIPStock Price: $8.05 (-$0.22)P/E Ratio: -7.82Market Cap: $309.76 millionAverage Trading Volume: 161,281 sharesConsensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $13.40 (66.5% Upside)Arteris, Inc. provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP. Its products include FlexNoC and FlexWay silicon-proven interconnect IP products; Ncore, a silicon-proven and cache coherent interconnect IP product that provides scalable, configurable, and area efficient characteristics; and CodaCache, a last-level cache semiconductor IP product. The company also offers SIA products comprising Magillem Connectivity that shortens and streamlines the SoC integration process; and Magillem Registers and CSRCompiler that addresses hardware-software integration challenges for SoCs. The company serves semiconductor manufacturers, original equipment manufacturers, hyperscale system houses, semiconductor design houses, and other producers of electronic systems. Arteris, Inc. was founded in 2003 and is headquartered in Campbell, California. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: GameStop is Roaring Based on Speculation Not Substance Why These Companies Are Buying Back Stock Lately Amazon and the Compelling Case for 30% Upside 3 Affordable Stocks That Won’t Stay Down Much Longer MarketBeat Week in Review – 5/6 - 5/10 Will the Surge in GameStop Stock Spark a New Meme Craze? New Highs in Sight For Symbotic and its AI Warehouse Automation Robinhood Soars: Dissecting a Record-Breaking Q1 2024 Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.